Molecular surveillance of Plasmodium vivax dhfr and dhps mutations in isolates from Afghanistan by Zakeri, Sedigheh et al.
RESEARCH Open Access
Molecular surveillance of Plasmodium vivax dhfr
and dhps mutations in isolates from Afghanistan
Sedigheh Zakeri
1*, Mandana Afsharpad
1, Faezeh Ghasemi
1, Ahmad Raeisi
2, Najibullah Safi
3, Waqar Butt
4,
Hoda Atta
5, Navid D Djadid
1
Abstract
Background: Analysis of dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps) mutations in
Plasmodium vivax wild isolates has been considered to be a valuable molecular approach for mapping resistance
to sulphadoxine-pyrimethamine (SP). The present study investigates the frequency of SNPs-haplotypes in the dhfr
and dhps genes in P. vivax clinical isolates circulating in two malaria endemic areas in Afghanistan.
Methods: P. vivax clinical isolates (n = 171) were collected in two different malaria endemic regions in north-west
(Herat) and east (Nangarhar) Afghanistan in 2008. All collected isolates were analysed for SNP-haplotypes at
positions 13, 33, 57, 58, 61, 117 and 173 of the pvdhfr and 383 and 553 of the pvdhps genes using PCR-RFLP
methods.
Results: All 171 examined isolates were found to carry wild-type amino acids at positions 13, 33, 57, 61 and 173,
while 58R and 117N mutations were detected among 4.1% and 12.3% of Afghan isolates, respectively. Based on
the size polymorphism of pvdhfr genes at repeat region, type B was the most prevalent variant among Herat (86%)
and Nangarhar (88.4%) isolates. Mixed genotype infections (type A/B and A/B/C) were detected in only 2.3% (2/86)
of Herat and 1.2% (1/86) of Nangarhar isolates, respectively. The combination of pvdhfr and pvdhps haplotypes
among all 171 samples demonstrated six distinct haplotypes. The two most prevalent haplotypes among all
examined samples were wild-type (86%) and single mutant haplotype I13P33F57S58T61N 117I173/A383A553 (6.4%).
Double (I13P33S57R58T61N117I173/A383A553) and triple mutant haplotypes (I13P33S57R 58T61N117I173/G383A553) were
found in 1.7% and 1.2% of Afghan isolates, respectively. This triple mutant haplotype was only detected in isolates
from Herat, but in none of the Nangarhar isolates.
Conclusion: The present study shows a limited polymorphism in pvdhfr from Afghan isolates and provides
important basic information to establish an epidemiological map of drug-resistant vivax malaria, and updating
guidelines for anti-malarial policy in Afghanistan. The continuous usage of SP as first-line anti-malarial drug in
Afghanistan might increase the risk of mutations in the dhfr and dhps genes in both P. vivax and Plasmodium
falciparum isolates, which may lead to a complete SP resistance in the near future in this region. Therefore,
continuous surveillance of P. vivax and P. falciparum molecular markers are needed to monitor the development of
resistance to SP in the region.
Background
Plasmodium vivax is responsible for approximately 70-
80 million cases of malaria worldwide and causes exten-
sive morbidity in Central and South America and Asia
[1]. The extension of geographic distribution of P. vivax,
the emergence of chloroquine (CQ) resistance [2,3] and
also reported fatal cases [4-6] are important issues in
developing control strategies. In fact, increasing morbid-
ity and mortality due to emergence of P. vivax resis-
tance to CQ [2-6] results in an urgent need to find
alternative treatments for P. vivax infection, including
antifolate drugs.
Molecular studies have been shown that point muta-
t i o n si nt h eg e n e st h a te n c o d e dihydrofolate reductase
(DHFR) and dihydropteroate synthase (DHPS) enzymes
(key enzymes in the biosynthesis and recycling
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any medium, provided the original work is properly cited.tetrahydrofolate) confer resistance to sulphadoxine-pyri-
methamine (SP) in both Plasmodium falciparum and
P. vivax parasites [7-12]. Moreover, the pvdhfr and
pvdhps genotypes might be associated with treatment
failure in individual vivax malaria patients [13].
Although data on the genotypes of these two genes are
available in Thailand, the Indian subcontinent and the
Indonesian archipelago, such data are limited in many
regions, most notably Central and South America and
the Middle East.
Different investigations showed that mutant alleles of
pvdhfr gene in areas with a long history of extensive SP
use are prevalent; however, wild-type pvdhfr has been
found more commonly in areas with limited use of SP
[8,10,13,14]. So far, over 20 different alleles have been
described in pvdhfr [15]. Also, different studies of
P. vivax parasites in various malaria endemic areas, such
as Thailand and India showed that mutations at pvdhfr
codons 57, 58, 61, 117 and 173, [8,16] were found to be
involved in clinical antifolate resistance [10,15]. Four
mutations have already been identified in pvdhps gene
at codons 382, 383, 442 and 553 [15,16].
Afghanistan is a country in south-central Asia, where
malaria has remained a major public health problem in
many of its provinces at altitudes below 2,000 metres
with low to high transmission potential. Malaria trans-
mission is seasonal from June to November and the
peak for P. vivax is around July, but is in October for
P. falciparum. According to WHO, Afghanistan has the
second highest burden of malaria in the Eastern Medi-
terranean Region (EMR) and the fourth highest rate
worldwide, including outside sub-Saharan Africa [17].
National Malaria Control Programmes initiated in 1950s
led to a substantial reduction of transmission in Afgha-
nistan, not only by using DDT, but also by increasing
the number of diagnosis of malaria patients and treat-
ment. However, the rate of malaria has increased due to
war and the lack of the malaria control programme in
this country.
After the invasion of the Soviet Union to Afghanistan,
the public health system collapsed, health professionals
emigrated and poverty increased. Therefore, this resulted
in increasing the rates of malaria than any other disease
in Afghanistan due to the lack of the malaria control pro-
gramme. Before the war, in 1970s, the number of
recorded cases of malaria per year varied between 40, 000
and 80,000 (an annual incidence of 2.5- 5 per 1000 peo-
ple). In 2002, the total malaria burden was estimated by
the WHO to be 2.2-3 million cases per year. In 2007, 19
cases of malaria per 1,000 population (466,239 total
reported cases) were reported; however, the estimated
cases by WHO is 1,500,000 [17].
The first detection of P. falciparum resistance to
chloroquine (CQ) was reported in 1989 and with an
increase to 90%, the Ministry of Public Health, National
Malaria Control Programme in Afghanistan, decided in
2004 to revise its treatment policy. Therefore, SP-artesu-
nate in combination has been recommended and being
used as the first-line anti-malarial treatment, which in
fact gives 100% cure rate [17]. CQ plus primaquine
remains the first choice drug for treatment of P. vivax
mono-infections and resistance to either CQ or SP has
not been recorded yet [17]. Furthermore, P. vivax is
sympatric with P. falciparum [18] in these areas, but the
correct diagnosis of mixed infections based on micro-
scopic examination of blood films is not easy and the
clinical symptoms caused by the two species cannot
be differentiated. As a result, P. vivax populations have
often been inadvertently exposed to SP pressure and
this may have caused the selection of P. vivax SP-resis-
tant isolates.
Molecular markers have been validated as tools for
surveillance of resistance; therefore, analysis of pvdhfr
and pvdhps mutations in wild isolates has been consid-
ered to be a valuable molecular approach for mapping
drug resistance and monitoring malaria control mea-
sures. This is the first study to investigate the frequency
of SNPs-haplotypes in the dhfr and dhps genes in
P. vivax clinical isolates circulating in two malaria ende-
mic areas in Afghanistan. Thus, the out-coming results
may be useful for establishing an epidemiological map
of drug-resistant vivax malaria, and also updating guide-
lines for anti-malarial policy in Afghanistan.
Methods
Study sites and collection of clinical isolates of P. vivax
Blood samples (n = 171) were collected from the
patients who were infected with P. vivax mono-infec-
tion, reported to the health facilities located in Herat
and Nangarhar provinces in Afghanistan. Herat, a pro-
v i n c ei nt h en o r t h - w e s to fA f g h a n i s t a no nt h eb o r d e r
between Iran and Turkmenistan, has 15 districts with a
population of around 1,182,000. Totally, 233 confirmed
cases with P. falciparum (n = 3) and P. vivax (n = 230)
were reported from public health facilities in 2008. Nan-
garhar is located in the east of Afghanistan on border
with Pakistan. The province has 21 districts with a
population of around 1,089,000. In 2008, 1352 and
28,823 confirmed cases with P. falciparum and P. vivax
were reported from public health facilities, respectively.
The risk of malaria transmission in both areas is moder-
ate to high. After obtaining informed consent from
adults or the parents or legal guardians of children, 1 ml
of blood was collected from vivax malaria patients on
admission, from April to September 2008. All P. vivax
clinical isolates (Nangarhar = 86 and Herat = 85) were
diagnosed by light microscopic examination of Giemsa-
stained blood smears. This study was approved by the
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teur of Iran.
Parasite genomic DNA extraction and pvdhfr/pvdps genes
amplification
Parasite DNA was extracted from 250 μli n f e c t e dw h o l e
blood by phenol/phenol-chloroform extraction and etha-
nol precipitation as described previously [19]. The DNA
was dissolved in 30 μl TE buffer (10 mM Tris-HCL, pH
8.0 and 0.1 mM EDTA). P. vivax isolates were genotyped
for dhfr and dhps genes by using previously described
PCR-RFLP methods [8,10,20] [Tables 1 and 2].
All amplifications were carried out in a final volume
of 25 μl including 1 μl of template from either genomic
DNA or the primary reaction. The primers were used at
a final concentration of 250 nM and the reaction mix-
ture contained 10 mM Tris-HCL (pH 8.3), 50 mM KCl,
2m MM g C l 2, each of the four deoxynucleotide tripho-
sphates at a concentration of 125 μM, and 0.2 U of Taq
polymerase (Invitrogen, Carlsbad, CA). The DNA frag-
ments, obtained following PCR amplification or RFLP
analysis, were electrophoresed on 2.5% and 3% Meta-
phor agarose gels (Invitrogen, Carlsbad, CA),
respectively.
Analysis of pvdhfr gene at repeat region
The region contains a tandem repeat was amplified
using 1 μl of primary reaction with the following pri-
mers as described previously [10]:
VDFN2F: CGGTGACGACCTACGTGGATGAGTCA
AAGT
VDFN2R: TAGCGTCTTGGAAAGCACGACGTT
GATTCT
The cycling conditions for this reaction was 95°C for
5 min, 25 cycles of 66°C for 2 min, 72°C for 2 min, 94°C
for 1 min followed by 66°C for 2 min and 72°C for 15
min. The DNA fragments obtained following PCR
amplification were analysed following electrophoresis on
3% Metaphor agarose gels. Three size variant types, A
(the largest bp), B (the middle bp) and C (the smallest
bp), ranging between 230 and 280 bp, were detected in
the studied samples.
Results
Detection of mutations in the pvdhfr and pvdhps genes
In this investigation, 171 isolates from Nangarhar and
Herat were analysed for SNPs-haplotypes at positions 13,
33, 57, 58, 61, 117 and 173 of the pvdhfr and 383 and 553
of pvdhps genes and also six pvdhfr/pvdhps alleles were
identified. In pvdhfr, polymorphisms at positions 58R and
117N were found in 2.3% and 13.9% of Nangarhar iso-
lates, respectively. Among Herat isolates, mutations at
positions 58R and 117N were found in 2.3% and 3.5% of
the studied isolates, respectively (Table 3).
In total, all 171 examined isolates were found to carry
wild-type amino acids at positions 13, 33, 57, 61 and 173,
while 58R and 117N mutations were detected among
4.1% and 12.3% examined samples, respectively (Table 3).
Table 1 Primers and profiles used for amplification of the pvdhfr and pvdhps genes.
Gene Nested-PCR
(position)
Primer Sequence Temperature °C/time (min) Product size (bp)
AEDC
Nest-1 VDTOF ATGGAGGACCTTTCAGATGTATTTGACATT 64 (2’)7 2 ( 2 ’)9 4 ( 1 ’) 25 1869
VDTOR GGCGGCCATCTCCATGGTTATTTTATCGTG
Nest-2
(13, 33, 58, 61)
VDF13NF GACCTTTCAGATGTATTTGACATTTACGGC 66 (2’)7 2 ( 2 ’)9 4 ( 1 ’) 25 232
VDF13NR GGTACCTCTCCCTCTTCCACTTTAGCTTCT
pvdhfr Nest-2
(57, 117)
VDNF57 CATGGAAATGCAACTCCGTCGATATGATGT 66 (2’)7 2 ( 2 ’)9 4 ( 1 ’) 25 472
VDFNR TCACACGGGTAGGCGCCGTTGATCCTCGTG
Nest-2
(57, 173)
VDTOF ATGGAGGACCTTTCAGATGTATTTGACATT 66 (2’)7 2 ( 2 ’)9 4 ( 1 ’) 25 608
VDFNR TCACACGGGTAGGCGCCGTTGATCCTCGTG
Nest-1 VDHPSOF ATTCCAGAGTATAAGCACAGCACATTTGAG 58 (2’)7 2 ( 1 ’)9 4 ( 1 ’) 21 1499
VDHPSOR CTAAGGTTGATGTATCCTTGTGAGCACATC
pvdhps Nest-2
(383)
VDHPSNF AATGGCAAGTGATGGGGCGAGCGTGATTGA 50 (2’)7 2 ( 2 ’)9 4 ( 1 ’) 25 703
VDHPSNR CAGTCTGCACTCCCCGATGGCCGCGCCACC
Nest-2
(553)
VDHPS553OF TTCTCTTTGATGTCGGCCTGGGGTTGGCCA 68 (1’)7 2 ( 1 ’)9 4 ( 1 ’) 30 170
VDHPSNR CAGTCTGCACTCCCCGATGGCCGCGCCACC
A: Annealing, E: Extension, D: Denaturation, C: Cycles
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both detected in 3.5% (3/86) of Nangarhar isolate but,
the mixed-genotype infection (117S/N) was only
detected in 3.5% (3/85) of Herat isolates (Table 3).
I nt h ec a s eo fpvdhps gene, polymorphisms at posi-
tions A383G and A553G of dhps were investigated and
mutation at 383G was only detected in 1.2% (1/85) of
Herat samples (Table 3). This mutation was also con-
firmed by sequencing analysis (accession no. Gu549414).
Repeat variation in pvdhfr gene
In this investigation, all three types (A, B and C) were
found among Afghan isolates. The frequency distribu-
tion for type A, B and C were 5.8% (5/86), 88.4%
(76/86) and 4.6% (4/86) among Nangarhar isolates,
respectively. However, for Herat samples, the prevalence
of type A, B and C were 9.4% (8/85), 86% (73/85) and
2.3% (2/85), respectively. Mixed-genotype infections
(type A/B) were detected in only 2.3% (2/85) of Herat
and mixed types (A/B/C) were detected in 1.2% (1/86)
of Nangarhar isolates (Figure 1).
Comparison of pvdhfr and pvdhps haplotypes in Afghan
isolates with that in other global geographical areas
The combination of pvdhfr and pvdhps haplotypes
among all 171 samples in this study demonstrated six
distinct haplotypes previously reported from various
geographic areas (Figure 2 and Additional file 1). The
two most prevalent haplotypes among all examined
samples were wild-type (86%) and
I13P33F57S58T61N117I173/A383A553 (6.4%). Alleles with
two mutations at position 58R and 117N
(I13P33F57R58T61N117I173/A383A553) accounted for 1.7%
of the total isolates and I13P33S57R58T61N117I173/
G383A553 (1.2%) mutant haplotype was only detected
among Herat but in none of the Nangarhar isolates (Fig-
ure 2 and Table 3). In addition, based on size poly-
morphism of pvdhfr genes at repeat region, type B was
Table 2 RFLP protocols used for genotyping pvdhfr and pvdhps genes.
Gene Primers RFLP Position Restriction Enzyme Company Uncut Product Size (bp) Cut Product
Size (bp)
VDF13NF/VDF13NR I13L Hae III Roche 232 L: 200 + 32
P33L Cfr42I (Sac II) Fermentas 232 P: 138 + 94
S58R Alu I Fermentas 232 S: 167 + 40 + 25
R: 207 + 25
T61M Tsp45 I BioLabs 232 T: 200 + 32
pvdhfr VDTOF/VDFNR F57I/L Xmn I Fermentas 608 F: 166 + 442
I173L Eco130 I (Sty I) Fermentas 608 L: 438 + 97 + 73
I: 472 + 136
VDNF57/VDFNR F57I/L BsrG I BioLabs 472 I: 444 + 28
S117N/T Pvu II BioLabs 472 S: 258 + 214
S117N/T Bsr I Fermentas 472 N: 219 + 253
S117N/T BstN I BioLabs 472 T: 257 + 215
Pvdhps
VDHPSNF/VDHPSNR A383G Msp I (Hpa II) Fermentas 703 G: 655 + 48
VDHPS553OF/VDHPSNR A553G MscI BioLabs 170 A:143 + 27
Table 3 The frequency distribution of SNPs combinations of pvdhfr and pvdhps alleles associated with sulphadoxine-
pyrimethamine in P. vivax isolates from Afghanistan.
pvdhfr pvdhps Nangarhar Herat
I13L P33L F57I/L S58R T61M S117N/T I173L A383G A553G n = 86 n = 85
I P F S T S I A A 68 (79.1%) 79 (92.9%)
IP F S T N I A A 10 (11.6%) 1 (1.2%)
IP F S T S N I A A 3 (3.5%) 3 (3.5%)
IP F R T N I A A 2 (2.3%) 1 (1.2%)
IP FS R T S I A A 3 (3.5%) -
IP F R T N I G A - 1 (1.2%)
R = 2.3% R = 2.4%
SR = 3.5% -
N = 13.9% N = 3.5%
SN = 3.5% SN = 3.5%
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and I13P33F57R58T61N117I173/A383A553 and
I13P33S57R58T61N117I173/G383A553 mutant haplotypes
were B type (Table 4).
The most common mutant haplotype is 58R/117N of
pvdhfr reported from other areas including Iran [21],
Pakistan [22], Thailand [23], India [24], Philippines,
Vietnam, East Timor, PNG, Vanuatu and Vietnam [25],
Colombia [15], Myanmar [26] and Madagascar [16], but
not from Azerbaijan and Turkey [27].
So far, quadruple mutant alleles of pvdhfr that are
associated with SP treatment failure were reported from
Myanmar [26], India [24], PNG, Vanuatu [25], and
Thailand [23] but not from other geographic areas
(Additional file 1). Double (383G/553G) and triple
Figure 1 Frequency distribution of pvdhfr repeat region types in wild P. vivax isolates from Afghanistan. A: Type A (the largest bp); B:
Type B (the middle bp); C: Type C (the smallest bp); ranging between 230 and 280 bp. A/B and A/B/C: Mixed genotype infections.
Figure 2 Frequency distribution of the combination pvdhfr/pvdhps haplotypes obtained from 171 isolates collected from Herat
province in north-west and Nangarhar province in eastern of Afghanistan. All six haplotypes are indicated as A to F in the Figure. Mutated
amino acids are boldfaced. A) I13P33F57S58T61S117I173/A383A553 B) I13P33F57S58T61N117I173/A383A553 C) I13P33F57S58T61SN117I173/A383A553 D)
I13P33F57R58T61N117I173/A383A553 E) I13P33F57SR58T61S117I173/A383A553 F) I13P33F57R58T61N117I173/G383A553.
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reported from Thailand [23] (Additional file 1).
Discussion
Efforts toward controlling malaria are greatly challenged
by the increasing spread of anti-malarial drug resistance
and also the use of ineffective anti-malarial drugs.
Therefore, there is a need for monitoring anti-malarial
drug efficacy and drug resistance in global malaria ende-
mic regions. In the present study, for the first time, the
prevalence of mutations in the SP resistance-associated
genes, dhfr and dhps was determined in 171 blood sam-
ples infected with P. vivax collected from two malaria
endemic areas of Afghanistan where both CQ and SP
were used for treatment. Vivax infections are not often
treated with SP; therefore, P. vivax isolates are exposed
to SP because mixed infections are present in these
regions and are often mis-diagnosed [18].
Afghanistan is a country in south-central Asia that bor-
d e r e dt ot h ew e s tw i t hI r a na n dt ot h ee a s ta n ds o u t h
with Pakistan. Due to war, population displacements and
movements across the borders have also occurred and
this might contribute to the spread of disease and also
parasite resistance to anti-malarial drugs to neighbouring
countries. Although there is no in vivo evidence of P.
vivax resistance to CQ in Afghanistan, an in vivo work in
Iran in 2005 [28] showed that parasite clearance time
increased when compared to 2001 in Sistan and Baluchi-
stan province. This indicates that it could be an early
sign of reduced susceptibility of the P. vivax populations
to CQ in these regions. Therefore, an effective alternative
drug against P. vivax resistance to CQ might be needed
in near future.
In the present investigation, a limited polymorphism in
pvdhfr and pvdhps genes has been detected that was in
contrast with earlier studies in Myanmar [26], PNG,
Vanuatu [25], and Thailand [23]. In total, six distinct hap-
lotypes of pvdhfr were detected among Afghan isolates.
The wild-type dhfr/dhps haplotype is present at high pro-
portion in P. vivax parasite populations from both study
areas in Afghanistan, which was similar to that of obtained
from malaria endemic regions in Iran [21] and Pakistan
[22]. The single mutant I13P33F57S58T61N117I173/A383A553
(6.4%) was the second frequent haplotype in Afghan
P. vivax isolates; however, double mutant
I13P33F57R58T61N117I173/A383A553 was the second frequent
haplotype in Iranian (9.5%) and Pakistani (16.1%) isolates
[21,22]. The explanation for low prevalence of
I13P33F57R58T61N117I173/A383A553 haplotype (1.7%) among
Afghan isolates may be due to the recent usage of SP as
the first-line anti-malarial treatment in these areas, as dif-
ferent studies revealed that wild-type pvdhfr has been
f o u n dm o r ec o m m o n l yi na r e a sw i t hl i m i t e du s eo fS P
[8,10,13,14]. Moreover, the frequency distribution of
pvdhfr mutant haplotypes was significantly higher in the
Nangarhar (20.9%) than Herat province (7%). This might
be also due to gene flow of SP resistance in P. vivax popu-
lations in a consequence of human migration across bor-
der between Pakistan and Afghanistan in Nangarhar
province.
Based on size polymorphism of pvdhfr gene at repeat
region, among Afghan isolates, type B was identified at
high proportion in both study areas similar to the find-
ings from its neighbouring country, Iran [21]. The pre-
sent investigation also showed the association between
mutant haplotypes and type B in both study areas; how-
ever final conclusion for such association needs further
study in global vivax malaria endemic region. In addi-
tion, mixed genotype infections, types A/B and A/B/C
Table 4 Association between mutations and tandem repeat region type of pvdhfr gene in P. vivax isolates from
Afghanistan.
Repeat region type pvdhfr pvdhps Nangarhar Herat
I13L P33L F57I/L S58R T61M S117N/T I173L A383G A553G n = 86 n = 85
A IP F S T N I A A 2 (2.3%) -
I P F S T S I A A 3 (3.5%) 8 (9.4%)
B IP F R T N I A A 2 (2.3%) 1 (1.2%)
IP F S T N I A A 8 (9.3%) 1(1.2%)
I P F S T S I A A 61 (71%) 67 (78.8%)
IP FS R T S I A A 3 (3.5%) -
IP F S T S N I A A 2 (2.3%) 3 (3.6%)
IP F S T N I G A - 1(1.2%)
C I P F S T S I A A 4 (4.6%) 2 (2.3%)
A/B I P F S T S I A A - 2 (2.3%)
A/B/C IP F S T S N I A A 1 (1.2%) -
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tively; however, the only mixed type detected in Iranian
malaria settings was B/C genotype [21].
The 58R and 117N were found in 4.1% and 12.3% of
all examined isolates, respectively and in combination
with each other (58R/117N) in 2.3%. Surprisingly, 117N
was detected at high frequency among isolates collected
from Turkey (36%), Azerbaijan (71%) and Pakistan
(93.5%) [22,27].
Mutations at codons 58 and 117 in pvdhfr gene are
also considered to be equivalent to mutations at resi-
dues 59 and 108 in pfdhfr, respectively that are known
to be associated with pyrimethamine resistance. In fact,
double mutations at codons 58R and 117N in pvdhfr
may arise first under drug pressure and move toward
the development of resistance to SP [8]. As a result,
these two mutations were detected in P. vivax popula-
tions in Iran [21], Pakistan [22] and Afghanistan [pre-
sent study] three years after using SP-artesunate as first-
line treatment of uncomplicated P. falciparum in these
regions. In the present study, quadruple mutants were
not detected among examined isolates; however, quad-
ruple mutant alleles of pvdhfr at codons 57, 58, 61 and
117 predominated in clinical isolates in Thailand, where
P. falciparum showed multi-drug resistance [23], Myan-
mar, Indonesia and India [8,10,26,29,30]. The difference
in the prevalence of mutant pvdhfr alleles reflects the
selection pressure exerted by usage of the antifolate
drug in these countries.
The work carried out by Tahar and colleagues [31]
showed that the 58R/117N mutant had a lower affinity
for pyrimethamine and cycloguanil than did the wild-
type enzyme. Different studies also showed that in areas
where antifolate has been intensively used, such as Thai-
land and Indonesian Papua, haplotypes that carry more
than two mutations of dhfr are more prevalent and
surely are resistance to pyrimethamine [8,10,14,27,32].
Patients whose parasites carried the 57L/61M/117T/
173F allele were more likely to fail SP treatment [14,29].
In addition, treatment failure was more frequently asso-
ciated with multiple mutations in pvdhfr and pvdhps
[20] and also when the parasite carries mutant alleles of
both genes, clinical effectiveness is compromised
[33-35]. In the present study, the most common haplo-
types of pvdhfr were wild-type and double mutant (58R
and 117N), quadruple mutant were not detected among
examined isolates. This suggests that a DHFR inhibitor
could be effective in treatment against the erythrocytic
stages of vivax malaria. In contrast, molecular analysis
of pvdhfr among Indian field isolates showed haplotypes
from wild-type to quadruple mutant genotype. These
haplotypes may be come from Indian subcontinent to
this area as gene flow of anti-malarial drug resistance in
malaria parasites might be often a consequence of
human migration rather than the emergence of new
mutations. Moreover, the results support the concept of
east to west reduction in SP pressure and this might be
reflected in the presence of different mutations in the
pvdhfr gene.
Conclusions
The present molecular data shows a limited polymorph-
ism in pvdhfr from Afghan isolates and it provides
important basic information for monitoring SP resis-
tance in Afghanistan. The present study shows high pre-
valence of wild-type and low frequency of single
mutated pvdhfr alleles among Afghan isolates. However,
the continuous SP pressure in Afghanistan might pro-
gress mutations in the dhfr gene in both P. vivax and P.
falciparum species, which may finally lead to a complete
SP resistance in this region. Therefore, continuous sur-
veillance of P. vivax and P. falciparum molecular mar-
kers are needed to monitor the development of
resistance to SP. Moreover, such information is neces-
sary for guiding malaria control measures in the frame
of Roll Back Malaria strategies for eliminating of malaria
in this region.
Additional file 1: Frequency distribution of different haplotypes of
pvdhfr and pvdhps in different geographic areas.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1475-2875-9-75-
S1.DOC]
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